Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026 Based on its unique mode of binding JAK2, AJ1-11095 has the potential to deliver deeper and more...
Hence then, the article about lilly to acquire ajax therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera )
Also on site :
- Former UFC Star Shot 3 Times in Deadly Congo Ambush While on Mission for Blackwater Founder’s Security Firm
- Tammy Wynette’s Favorite Song Reimagined By ’70s Music Star 50 Years Later for Star-Studded Tribute Concert
- In 1970, Oregon highway crews packed a dead 45-foot sperm whale with a half-ton of dynamite; the blast rained blubber on spectators and crushed a new car a quarter-mile away